Funder
Israel Science Foundation
Proteomass Scientific Society
Fundacao para a Ciencia e a Tecnologia
LAQV-REQUIMTE
Reference39 articles.
1. Multiple myeloma: 2022 update on diagnosis, risk stratification, and management;Rajkumar;Am. J. Hematol.,2022
2. ‘Multiple myeloma incidence and mortality around the globe; interrelations between health access and quality, economic Resources, and;Ludwig;Patient Empowerment’, Oncologist,2020
3. Trends in solitary plasmacytoma, extramedullary plasmacytoma, and plasma cell myeloma incidence and myeloma mortality by racial‐ethnic group, United States 2003‐2016;Ellington;Cancer Med.,2021
4. Unbiased cell surface proteomics identifies SEMA4A as an effective immunotherapy target for myeloma;Anderson;Blood,2022
5. Single-cell proteomics and tumor RNAseq identify novel pathways associated with clofazimine sensitivity in PI- and IMiD- resistant myeloma, and putative stem-like cells;Kumar;Front. Oncol.,2022